Discoveries in Multiple Myeloma

Discoveries in Multiple Myeloma

Source:

Munshi NC, et al. Abstract 8503. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.

Disclosures: Munshi reports stock and other ownership interests in OncoPep; consultant/advisory roles with AbbVie, Adaptive Biotechnologies, Amgen, BeiGene, Bristol-Myers Squibb, Celgene, Janssen, Karyopharm Therapeutics, OncoPep and Takeda; and patents, royalties and other intellectual property with OncoPep.
June 15, 2020
1 min watch
Save

VIDEO: BCMA-targeted CAR T offers ‘attractive option’ for advanced multiple myeloma

Source:

Munshi NC, et al. Abstract 8503. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.

Disclosures: Munshi reports stock and other ownership interests in OncoPep; consultant/advisory roles with AbbVie, Adaptive Biotechnologies, Amgen, BeiGene, Bristol-Myers Squibb, Celgene, Janssen, Karyopharm Therapeutics, OncoPep and Takeda; and patents, royalties and other intellectual property with OncoPep.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Nikhil C. Munshi, MD, from Dana-Farber Cancer Institute, discussed initial results from the KarMMa trial of idecabtagene vicleucel, a BCMA-targeted CAR T-cell therapy, which he presented at ASCO20 Virtual Scientific Program.

In this phase 2 study, treatment resulted in demonstrated deep, durable responses in heavily pretreated patients with relapsed and refractory multiple myeloma.

“Idecabtagene vicleucel is a really important treatment in this patient population. Toxicity is manageable, so it’s an attractive option for people who have been exposed to the three classes of drug in the relapsed or refractory setting,” he said in the video.